Back to Business

KB Home earnings beat by $0.16, revenue was in line with estimates

Business September 22, 2026 at 8:14 PM

KB Home earnings beat by $0.16, revenue was in line with estimates

Investing.com

Read at Investing.com

More Stories

Wedbush downgrades Compass Therapeutics stock rating on FDA trial concerns

Wedbush downgrades Compass Therapeutics stock rating on FDA trial concerns

🇺🇸 Investing.com 31m ago

Porch Group stock initiated with buy rating at Texas Capital

Porch Group stock initiated with buy rating at Texas Capital

🇺🇸 Investing.com 31m ago

Halozyme Therapeutics completes $1.5 billion convertible notes offering

Halozyme Therapeutics completes $1.5 billion convertible notes offering

🇺🇸 Investing.com 31m ago

Your world briefing, in your pocket

AI-curated news from 12 countries and 10 languages — coming soon on iOS and Android.

Coming soon on App Store Coming soon on Google Play